Bringing the benefits of anticoagulation management services to the community

Canadian Pharmacists Journal

Volumn 139, Issue 2, 2006, Pages 58-64

  Bungard, Tammy J ^a   Archer, Stephen L ^a   Hamilton, Peter ^a   Ritchie, Bruce ^a   Tymchak, Wayne ^a   Tsuyuki, Ross T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ALLIED HEALTH EDUCATION; ANTICOAGULANT THERAPY; CANADA; COMMUNITY CARE; COST BENEFIT ANALYSIS; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; PATIENT EDUCATION; PATIENT REFERRAL; PHARMACIST; REVIEW; SOCIAL WELFARE; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

EID: 33744456237     PISSN: 17151635     EISSN: None     Source Type: Journal    
DOI: 10.1177/171516350613900207     Document Type: Review

References (39)

1. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Chest 2004;126(3 Suppl):126S-696S.
2. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
4. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
5. Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322:428-32.
6. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-51.
7. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
8. Petersen P, Boysen G, Godfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989;177:175-9.
9. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.
10. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
11. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-6.
12. The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998;14:695-702.
13. Tsuyuki RT, Walters B, Teo KK. Antithrombotic use in atrial fibrillation - an update. Can J Cardiol 2000;16:99.
14. Bungard TJ, Ackman ML, Ho G, Tsuyuki RT. Warfarin therapy amongst patients with atrial fibrillation admitted to hospital. Pharmacotherapy 2000;20:1060-5.
15. Burkeiwicz JS. Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation. Pharmacotherapy 2005;25(8):1062-7.
16. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH, and the Anticoagulation Guidelines Task Force. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother 1997;31:604-15.
17. Bussey HI, Chiquette E, Amato MG. Anticoagulation clinic care versus routine medical care: a review and interim report. J Thromb Thrombolysis 1996;2:315-9.
18. Bussey HI, Respond RM, Quandt CM, Clark GM. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy 1989;9:214-9.
19. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
20. Charney R, Leddomando E, Rose DN, Fuster V. Anticoagulation clinics and the monitoring of anticoagulant therapy. Int J Cardiol 1988;18:197-206.
21. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998;158:1641-7.
22. Cohen IA, Hutchinson TA, Kirking DM, Shue ME. Evaluation of a pharmacist-managed anticoagulation clinic. J Clin Hosp Pharm 1985;10:167-75.
23. Conte RR, Kehoe WA, Nielson N, Lodhia H. Nine-year experience with a pharmacist-managed anticoagulation clinic. Am J Hosp Pharm 1986;43:2460-4.
24. Cortelazzo S, Finazzi G, Viero P, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haem 1993;69:316-20.
25. Davis FB, Estruch MT, Samson-Corvera EB, Boigt GC, Tobin JD. Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal setting. Arch Intern Med 1977;137:197-202.
26. Ellis RF, Stephens MA, Sharp GB. Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy. Am J Hosp Pharm 1992;49:387-94.
27. Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: experience with an anticoagulation clinic. Arch Intern Med 1984;144:1966-8.
28. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993;118:511-20.
29. Fofar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Brit Heart J 1979;42:128-32.
30. Garabedian-Ruffalo SM, Gray DR, Sax MJ, Ruffalo RL. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm 1985;10:167-75.
31. Hamilton GM, Childers RW, Silverstein MD. Does clinic management of anticoagulation improve the outcome of prosthetic valve patients? Clin Res 1985;33:832A.
32. Petty GW, Lennihan L, Mohr JP, Hauser WA, Weitz J, Owen J, Towey C. Complications of long-term anticoagulation. Ann Neurol 1988;23:570-4.
33. Radley AS, Hall J, Farrow M, Carey PJ. Evaluation of anticoagulant control in a pharmacist operated anticoagulant clinic. J Clin Pathol 1995;48:545-7.
34. Rivey MP, Wood RD, Allington DR, Stratton TP, Erickson CC, Stenson TA. Pharmacy-managed protocol for warfarin use in orthopedic surgery patients. Am J Health-Syst Pharm 1995;52:1310-6.
35. Seabrook GR, Karp D, Schmitt DD, Bandyk DF, Towne JB. An outpatient anticoagulation protocol managed by a vascular nurse-clinician. Am J Surg 1990;160:501-5.
36. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993;153:1557-62.
37. Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 1995;15:732-9.
38. Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulant clinics and by family physicians: a randomized controlled trial. CMAJ 2003;169(4):293-8.
39. Matchar DB, Samsa GP, Cohen SJ, et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 2002;113:42-51.